AI Nurse set to transform standards of care for heart failure patients in China

A fast-paced Novartis joint development project with one of the world’s largest technology companies has created an innovative, AI-enabled digital nurse to support heart failure patients in China.

Co-developed with China’s internet multinational Tencent, together with leading Chinese medical organizations, AI Nurse launched on April 30 and will serve as a patient needs-led intelligent platform supporting patients, physicians and nurses to better manage heart disease.

…

/by

Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum

  • Cosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) disease spectrum
     
  • There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US1
     
  • Cosentyx is also approved for the treatment of moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)2-4
      …
/by

Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia. CRS could lead to life-threatening complications in patients with COVID-191-3.

The study builds on early evidence from lab tests of COVID-19 patients who showed elevated IL-1β levels, among other cytokines2,4.

…

/by

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

  •   Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz:
    • Key growth drivers include Entresto USD 569 million (+62% cc), Zolgensma USD 170 million, Cosentyx USD 930 million (+19% cc), Kisqali USD 161 million (+82% cc) and Piqray USD 74 million
    • Biopharmaceuticals grew 31% (cc) to USD 450 million, with strong growth in Europe
    • Excluding COVID-19 related forward purchases, we estimate3 sales …
/by

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

  • Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz:
    • Key growth drivers include Entresto USD 569 million (+62% cc), Zolgensma USD 170 million, Cosentyx USD 930 million (+19% cc), Kisqali USD 161 million (+82% cc) and Piqray USD 74 million
    • Biopharmaceuticals grew 31% (cc) to USD 450 million, with strong growth in Europe
    • Excluding COVID-19 related forward purchases, we estimate3 sales …
/by

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

  • Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz:
    • Key growth drivers include Entresto USD 569 million (+62% cc), Zolgensma USD 170 million, Cosentyx USD 930 million (+19% cc), Kisqali USD 161 million (+82% cc) and Piqray USD 74 million
    • Biopharmaceuticals grew 31% (cc) to USD 450 million, with strong growth in Europe
    • Excluding COVID-19 related forward purchases, we estimate3 sales …
/by

A visual tour of scientific strategies for combating coronavirus

Scientists worldwide have united against a common enemy: COVID-19, the illness caused by the novel coronavirus SARS-CoV-2. Their aim? Slow and eventually stop the pandemic by joining forces and working rapidly on near-term and long-term solutions.

The following collection of images illustrates the range of ideas, from repurposing existing medicines to developing vaccines to searching for completely new ways to attack coronaviruses.

In the near term, researchers are focused on repurposing existing medicines. Existing medicines are available now and researchers already know a lot …

/by

Novartis announces flexible return to office and on-site field activities, starting May 11, 2020

Starting May 11, 2020, Novartis will introduce company-wide a flexible working model that invites associates, country-by-country, to return to the office and restart on-site field activities, when possible and appropriate, based on the respective local situation and risk assessment. This is applicable to all countries and markets.

The health, wellbeing and safety of our associates remains paramount. This means each country leadership team, in accordance with local authorities, will decide when and how to loosen or tighten restrictions and voluntarily offer associates the opportunity …

/by

Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease

  • Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond to first-line steroid treatment1
     
  • Results show 62% overall response rate with Jakavi at Day 28, the primary endpoint of the study, compared to 39% for best available therapy1
     
  • GvHD is a serious and common complication of allogeneic stem cell transplants with a one-year death rate as high as 80% in its …
/by